Abstract
Objectives
The aim of the current statement is to agree on: (1) what is the current situation with education and training on dementia in Europe; (2) what are the minimum educational requirements for professionals (neurologists, psychiatrists, primary care providers, nurses, biologists, neuroradiologists, etc.) regarding Alzheimer’s disease and dementia, and (3) how to start a course of action for the future.
Design
In 2005, a simple questionnaire was sent to members of the European Alzheimer’s Disease Consortium (EADC) concerning the education and training on dementia in their countries. Fourteen universities of the respective countries responded to this simple questionnaire. The answers varied, and the conclusion of this effort was that little was done concerning the training of students and health professionals on dementia. In 2008, another more structured and specified questionnaire was sent to professors in different universities of the same countries.
Results
The answers obtained were different from those of the previous questionnaire and demonstrated that it is very difficult to know about training and education in the field of dementia in every European country.
Conclusion
From the data collected, it seems that although in the recent past little had been done concerning training on dementia, nowadays training has been developed in most European countries, and relevant educational projects exist both for medical students and doctors during their specialty training. Our main purpose is to develop training material or develop specific courses to improve the professional knowledge about dementia so that best medical and non-medical practice is implemented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin. 1907
Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry 1997; 12: 841–56
Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125–132.
Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer’s Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–2117.
Wimo A, Winblad, B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics. 2003;21:327–340.
Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother. 2005;3:39–49.
Meek PD, McKeithan K, Schumock GT. Economic considerations in Alzheimer’s disease. Pharmacotherapy. 1998;18:68–73.
Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rossor M. Diagnosis and management of Alzheimer’s disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol. 2000;7:133–144.
National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer’s disease. Available from URL: http://www.nice.org.uk/pdf/ALZHEIMER_full_guidance. pdf [Accessed 16 June 2009].
Ruof J, Mittendorf T, Pirk O, von der Schulenburg JM. Diffusion of innovations: treatment of Alzheimer’s disease in Germany. Health Policy. 2002;60:59–66.
Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapicchio P, Senin U, Trabucchi M, Musicco M; Italian Association of Psychogeriatrics. Guidelines for the Treatment of Alzheimer’s Disease from the Italian Association of Psychogeriatrics. Drugs & Aging 2005; 22:1–26.
Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman H, Hogan DB. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 1999;15: S1–15.
Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179:787–793.
Burns A, O’Brien J, BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20:732–755.
Hasselbalch SG, Baloyannis S, Denislic M, Dubois B, Oertel W, Rossor M, Tsiskaridze A, Waldemar G. Education and training of European neurologists in dementia. Eur J Neurol. 2007;14:505–509.
Pfizer Pharmaceuticals. Model Scenario and course on the formation of keypersons. Knowledge of and attitudes to Dementia, 1997.
Nivalis, Circle of care for Professionals and for Relatives. The trained professional Janssen Cilag Academy.
Tsolaki M, Papaliagkas V et al. Education of Professionals on Alzheimer’s Disease. Eur J of Neurol. 2005;12:294.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Tsolaki, M., Papaliagkas, V., Anogianakis, G. et al. Consensus statement on dementia education and training in Europe. J Nutr Health Aging 14, 131–135 (2010). https://doi.org/10.1007/s12603-009-0238-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-009-0238-z